Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials

por Ellingsen, Espen Basmo, Aamdal, Elin, Guren, Tormod, Lilleby, Wolfgang, Brunsvig, Paal F, Mangsbo, Sara M, Aamdal, Steinar, Hovig, Eivind, Mensali, Nadia, Gaudernack, Gustav, Inderberg, Else Marit
Publicado 2022

Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial

por Aamdal, Elin, Inderberg, Else Marit, Ellingsen, Espen Basmo, Rasch, Wenche, Brunsvig, Paal Fredrik, Aamdal, Steinar, Heintz, Karen-Marie, Vodák, Daniel, Nakken, Sigve, Hovig, Eivind, Nyakas, Marta, Guren, Tormod Kyrre, Gaudernack, Gustav
Publicado 2021

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination

por Ellingsen, Espen Basmo, Bounova, Gergana, Kerzeli, Iliana, Anzar, Irantzu, Simnica, Donjete, Aamdal, Elin, Guren, Tormod, Clancy, Trevor, Mezheyeuski, Artur, Inderberg, Else Marit, Mangsbo, Sara M., Binder, Mascha, Hovig, Eivind, Gaudernack, Gustav
Publicado 2022